Curewell Capital in its formation of Curewell Capital I, a $535 million middle-market healthcare fund.
Butterfly Equity in its $527 million continuation fund transaction involving Qdoba.
A private market investment strategy on its subscription-based credit facility.
Castlelake, L.P. on the formation and fundraising of Castlelake Aviation V Stable Yield, L.P. and certain related aviation strategy investment vehicles, accounts and co-investments.
The Carlyle Group on the final closing of its fifth Japan-focused private equity fund, Carlyle Japan Partners V.
Hildred Capital backed-Crown Laboratories in its proposed $924 million acquisition of and subsequent $325 million amended merger agreement to acquire Revance Therapeutics.
Hildred Capital on the final closing of Hildred Equity Partners III.
